TITLE

Risk-Based Thinking in Process Validation

AUTHOR(S)
Agalloco, James
PUB. DATE
February 2011
SOURCE
Pharmaceutical Technology;Feb2011, Vol. 35 Issue 2, p68
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The US Food and Drug Administration's draft process-validation guidance changes regulatory expectations by requiring manufacturers to validate their processes by performing enough tests to achieve statistical significance. The author describes why statistical significance, which industry had rejected, would impose an unreasonable burden on manufacturers and provide little, if any, benefit.
ACCESSION #
58546688

 

Related Articles

  • Will medications be safer in the future? Erickson, Amy K. // Pharmacy Today;Nov2010, Vol. 16 Issue 11, p40 

    The article focuses on issues faced by the U.S. Food and Drug Administration (FDA) concerning safety and quality of drugs manufactured abroad. It highlights on the regulatory system implemented by FDA to ensure that products made outside the U.S. meet the standards of the pharmaceutical...

  • New Era for Generic Drugs. Wechsler, Jill // BioPharm International;Oct2012, Vol. 25 Issue 10, p13 

    The article discusses the Generic Drug User Fee Amendments of 2012 (GDUFA) program meant to reduce the time taking process for the approval of new generic drugs. It informs that generic-drug makers have agreed to provide funds to the U.S. Food and Drug Administration (FDA) in order to support...

  • As I See It. Dickinson, James G. // Medical Marketing & Media;Feb2010, Vol. 45 Issue 2, p30 

    The author discusses the importance of transparency in the drug safety review process of the U.S. Food and Drug Administration (FDA). He states that the Transparency Task Force was not able to produce the findings of FDA drug safety review process. He notes that detailed public summaries of...

  • Pharma bracing for tougher FDA guidance on trials. P., SHANKAR // njbiz;11/2/2009, Vol. 22 Issue 44, p4 

    The article reports that U.S. pharmaceutical companies are facing more stringent requirements from the Food and Drug Administration (FDA) on disclosures of accidents in clinical trials. The FDA requires pharmaceutical companies to inform the general public about disclosures on "adverse" and...

  • Industry Watch.  // AARC Times;Aug2010, Vol. 34 Issue 8, p76 

    The article offers updates related to pharmaceutical industry in the U.S. SonarMed Inc. has received clearance from U.S. Food and Drug Administration (FDA) for its patented SonarMed Airway Monitoring System (AIMS). A new website for Sporicidin located at www.sporicidin.com was launched by Contec...

  • The Metrics of Quality Culture. Harrison, Andrew; Schniepp, Susan // Pharmaceutical Technology;Sep2015, Vol. 39 Issue 9, p22 

    The article discusses the guidance for quality metrics proposed by the U.S Food & Drug Administration (USFDA). Topics discussed include passage of the Food and Drug Administration Safety and Innovation Act (FDASIA) to prevent drug shortage, use of the guidance by pharmaceutical industries to...

  • Age-Related Disorder. Lowe, Derek B. // Contract Pharma;Jan/Feb2013, Vol. 15 Issue 1, p30 

    The article focuses on disorders associated to aging and the discovery of drugs for these diseases by pharmaceutical companies in the U.S. It notes the scrutiny whether a drugmaker intends to sell medication for unapproved uses. It considers the ability of the Food and Drug Administration (FDA)...

  • DRUGS & MONEY. Novarro, Leonard // H&HN: Hospitals & Health Networks;08/05/97, Vol. 71 Issue 15, p54 

    Discusses the financial data of pharmaceutical companies in pouring unprecedented sums in research and development without guarantee that their drug will pass the Food and Drug Administration (FDA) scrutiny. Information about Remune, a human immunodeficiency virus (HIV) vaccine of Immune...

  • FDA shaping pharmaceutical sector. Wilkins, Jonathan // Manufacturers' Monthly;Nov2014, p48 

    The article discusses updates on code of federal regulations (CFR) by U.S. Food and Drug Administration (FDA) that requires any body manufacturing and testing pharmaceuticals to abide by these codes. Topics include improvements in automated procedures, maintenance of electronic records,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics